J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Jafron Biomedical Co Ltd stock under the Base Case scenario is 46.98 CNY. Compared to the current market price of 29.87 CNY, Jafron Biomedical Co Ltd is Undervalued by 36%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
46.98 CNY
Undervaluation 36%
Intrinsic Value
Price
J
Worst Case
Base Case
Best Case

Valuation Backtest
Jafron Biomedical Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Jafron Biomedical Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Jafron Biomedical Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Jafron Biomedical Co Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Jafron Biomedical Co Ltd

Provide an overview of the primary business activities
of Jafron Biomedical Co Ltd.

What unique competitive advantages
does Jafron Biomedical Co Ltd hold over its rivals?

What risks and challenges
does Jafron Biomedical Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Jafron Biomedical Co Ltd.

Provide P/S
for Jafron Biomedical Co Ltd.

Provide P/E
for Jafron Biomedical Co Ltd.

Provide P/OCF
for Jafron Biomedical Co Ltd.

Provide P/FCFE
for Jafron Biomedical Co Ltd.

Provide P/B
for Jafron Biomedical Co Ltd.

Provide EV/S
for Jafron Biomedical Co Ltd.

Provide EV/GP
for Jafron Biomedical Co Ltd.

Provide EV/EBITDA
for Jafron Biomedical Co Ltd.

Provide EV/EBIT
for Jafron Biomedical Co Ltd.

Provide EV/OCF
for Jafron Biomedical Co Ltd.

Provide EV/FCFF
for Jafron Biomedical Co Ltd.

Provide EV/IC
for Jafron Biomedical Co Ltd.

Show me price targets
for Jafron Biomedical Co Ltd made by professional analysts.

What are the Revenue projections
for Jafron Biomedical Co Ltd?

How accurate were the past Revenue estimates
for Jafron Biomedical Co Ltd?

What are the Net Income projections
for Jafron Biomedical Co Ltd?

How accurate were the past Net Income estimates
for Jafron Biomedical Co Ltd?

What are the EPS projections
for Jafron Biomedical Co Ltd?

How accurate were the past EPS estimates
for Jafron Biomedical Co Ltd?

What are the EBIT projections
for Jafron Biomedical Co Ltd?

How accurate were the past EBIT estimates
for Jafron Biomedical Co Ltd?

Compare the revenue forecasts
for Jafron Biomedical Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Jafron Biomedical Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Jafron Biomedical Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Jafron Biomedical Co Ltd compared to its peers.

Compare the P/E ratios
of Jafron Biomedical Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Jafron Biomedical Co Ltd with its peers.

Analyze the financial leverage
of Jafron Biomedical Co Ltd compared to its main competitors.

Show all profitability ratios
for Jafron Biomedical Co Ltd.

Provide ROE
for Jafron Biomedical Co Ltd.

Provide ROA
for Jafron Biomedical Co Ltd.

Provide ROIC
for Jafron Biomedical Co Ltd.

Provide ROCE
for Jafron Biomedical Co Ltd.

Provide Gross Margin
for Jafron Biomedical Co Ltd.

Provide Operating Margin
for Jafron Biomedical Co Ltd.

Provide Net Margin
for Jafron Biomedical Co Ltd.

Provide FCF Margin
for Jafron Biomedical Co Ltd.

Show all solvency ratios
for Jafron Biomedical Co Ltd.

Provide D/E Ratio
for Jafron Biomedical Co Ltd.

Provide D/A Ratio
for Jafron Biomedical Co Ltd.

Provide Interest Coverage Ratio
for Jafron Biomedical Co Ltd.

Provide Altman Z-Score Ratio
for Jafron Biomedical Co Ltd.

Provide Quick Ratio
for Jafron Biomedical Co Ltd.

Provide Current Ratio
for Jafron Biomedical Co Ltd.

Provide Cash Ratio
for Jafron Biomedical Co Ltd.

What is the historical Revenue growth
over the last 5 years for Jafron Biomedical Co Ltd?

What is the historical Net Income growth
over the last 5 years for Jafron Biomedical Co Ltd?

What is the current Free Cash Flow
of Jafron Biomedical Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Jafron Biomedical Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Jafron Biomedical Co Ltd

Current Assets 3.2B
Cash & Short-Term Investments 2.7B
Receivables 120m
Other Current Assets 348.6m
Non-Current Assets 2.2B
Long-Term Investments 116.1m
PP&E 1.9B
Intangibles 110.8m
Other Non-Current Assets 122.6m
Current Liabilities 1B
Accounts Payable 133.1m
Accrued Liabilities 116.9m
Short-Term Debt 338.8m
Other Current Liabilities 420.1m
Non-Current Liabilities 1.4B
Long-Term Debt 1.2B
Other Non-Current Liabilities 159.6m
Efficiency

Earnings Waterfall
Jafron Biomedical Co Ltd

Revenue
2.4B CNY
Cost of Revenue
-518.3m CNY
Gross Profit
1.9B CNY
Operating Expenses
-1B CNY
Operating Income
856.6m CNY
Other Expenses
-145.1m CNY
Net Income
711.5m CNY

Free Cash Flow Analysis
Jafron Biomedical Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Jafron Biomedical Co Ltd's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Gross Profit
Positive Operating Income
73/100
Profitability
Score

Jafron Biomedical Co Ltd's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Jafron Biomedical Co Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
73/100
Solvency
Score

Jafron Biomedical Co Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Jafron Biomedical Co Ltd

Wall Street analysts forecast Jafron Biomedical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Jafron Biomedical Co Ltd is 43.26 CNY with a low forecast of 42.83 CNY and a high forecast of 44.53 CNY.

Lowest
Price Target
42.83 CNY
43% Upside
Average
Price Target
43.26 CNY
45% Upside
Highest
Price Target
44.53 CNY
49% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Jafron Biomedical Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Jafron Biomedical Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Jafron Biomedical Co Ltd

Country

China

Industry

Health Care

Market Cap

24.1B CNY

Dividend Yield

1.34%

Description

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Contact

GUANGDONG
Zhuhai
No. 98 Keji 6th Road, High-tech District
+867563619693
www.jafron.com

IPO

2016-08-02

Employees

2 887

Officers

Chairman of Board of Directors & GM
Mr. Fan Dong
Director & Financial Director
Ms. Xueyun Liao
Deputy GM & Director
Ms. Xian Min Tang
Deputy General Manager
Mr. Aijun Wu
General Manager
Mr. Rui Wang
Board Secretary
Ms. Cong Huang

See Also

Discover More
What is the Intrinsic Value of one Jafron Biomedical Co Ltd stock?

The intrinsic value of one Jafron Biomedical Co Ltd stock under the Base Case scenario is 46.98 CNY.

Is Jafron Biomedical Co Ltd stock undervalued or overvalued?

Compared to the current market price of 29.87 CNY, Jafron Biomedical Co Ltd is Undervalued by 36%.

Back to Top